SCHEMBL2725872

SCHEMBL2725872

CC(C)n1c(Nc2ccc(C(=O)Nc3ccccc3N)cc2)nc2ccccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.57
ALDH1A1 P00352 1/20 0.51
KMT2A Q03164 1/20 0.51
POLB P06746 1/20 0.51
HDAC1 Q13547 12/20 0.49
HDAC2 Q92769 8/20 0.49
HDAC3 O15379 7/20 0.49
NCOR2 Q9Y618 4/20 0.49
IRAK4 Q9NWZ3 1/20 0.48
PDE11A Q9HCR9 1/20 0.47
PDE10A Q9Y233 1/20 0.47
MAPK1 P28482 1/20 0.47
HDAC4 P56524 2/20 0.46
HDAC7 Q8WUI4 2/20 0.46
HDAC10 Q969S8 2/20 0.46
HDAC11 Q96DB2 2/20 0.46
HDAC8 Q9BY41 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46
HDAC9 Q9UKV0 2/20 0.46
HDAC5 Q9UQL6 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9109386 0.92 HDAC6 (0.54) HSD17B10ALDH1A1KMT2APOLBHDAC1
SCHEMBL9910547 0.88 PDE11A (0.58) HSD17B10ALDH1A1HDAC1HDAC2HDAC3
SCHEMBL18263887 0.83 HSD17B10 (0.67) HSD17B10ALDH1A1KMT2APOLBHDAC1
SCHEMBL2724129 0.83 HSD17B10 (0.52) HSD17B10ALDH1A1KMT2APOLBIRAK4
SCHEMBL12974295 0.82 KDM4E (0.63) HSD17B10ALDH1A1KMT2AIRAK4NPC1
SCHEMBL2726254 0.81 TP53 (0.56) HSD17B10ALDH1A1KMT2AHDAC1HDAC2
SCHEMBL2724437 0.81 HSD17B10 (0.74) HSD17B10ALDH1A1KMT2APOLBIRAK4
SCHEMBL4982506 0.79 HDAC1 (0.60) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL2725093 0.78 HSD17B10 (0.67) HSD17B10ALDH1A1KMT2APOLBIRAK4
SCHEMBL18132836 0.76 NPC1 (0.60) HSD17B10ALDH1A1KMT2APOLBPDE11A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160362382-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL DRUG DEVELOPMENT, LLC 2016-12-15 US claimed
US-9125901-B2 4-(benzimidazol-2-ylamino)benzamide derivatives and salts or solvates thereof THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2015-09-08 US claimed
US-10590088-B2 4-(benzimidazol-2-ylamino)benzamide derivatives and methods of synthesis thereof TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) 2020-03-17 US disclosed
US-10590088-B2 4-(benzimidazol-2-ylamino)benzamide derivatives and methods of synthesis thereof TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) 2020-03-17 US disclosed
US-20190084940-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL DRUG DEVELOPMENT, LLC 2019-03-21 US disclosed
US-20190084940-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL DRUG DEVELOPMENT, LLC 2019-03-21 US disclosed
US-20160362382-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL DRUG DEVELOPMENT, LLC 2016-12-15 US disclosed
US-20160362382-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL DRUG DEVELOPMENT, LLC 2016-12-15 US disclosed
US-20160362382-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL DRUG DEVELOPMENT, LLC 2016-12-15 US disclosed
US-9464059-B2 Benzamide derivatives THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2016-10-11 US disclosed
US-9464059-B2 Benzamide derivatives THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2016-10-11 US disclosed
US-9125901-B2 4-(benzimidazol-2-ylamino)benzamide derivatives and salts or solvates thereof THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2015-09-08 US disclosed
EP-2445345-B1 BENZAMIDE DERIVATIVES TRANSLATIONAL GENOMICS RES INST (US) 2014-08-27 EP disclosed
EP-2445345-B1 BENZAMIDE DERIVATIVES TRANSLATIONAL GENOMICS RES INST (US) 2014-08-27 EP disclosed
US-20120142922-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2012-06-07 US disclosed
US-20120142922-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2012-06-07 US disclosed
US-20120142922-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2012-06-07 US disclosed
EP-2445345-A1 BENZAMIDE DERIVATIVES The Translational Genomics Research Institute (US) 2012-05-02 EP disclosed
WO-2010151441-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2010-12-29 WO disclosed
WO-2010151441-A1 BENZAMIDE DERIVATIVES TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10590088-B2 4-(benzimidazol-2-ylamino)benzamide derivatives and methods of synthesis thereof MCL1, BRDT, BOD1L1 HSD17B10 2881/4885ALDH1A1 400/4885KMT2A 370/4885
US-20120142922-A1 BENZAMIDE DERIVATIVES BRDT, BRD3, BRD2 HSD17B10 2696/4885ALDH1A1 592/4885KMT2A 520/4885
US-20160362382-A1 BENZAMIDE DERIVATIVES BRDT, BRD3, BRD2 HSD17B10 2696/4885ALDH1A1 592/4885KMT2A 520/4885
US-20190084940-A1 BENZAMIDE DERIVATIVES BRDT, BRD3, BRD2 HSD17B10 2696/4885ALDH1A1 592/4885KMT2A 520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.